CAMRF (Camurus AB) Moat Score: 5/10 (As of Jun. 25, 2026)


CAMRF Camurus AB CAMRF
79 GF Score
Price $54.00
GF Value $83.22
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Moat Score?

Camurus AB CAMRF -3.57% 79 Moat Score is 5 as of Jun. 25, 2026. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.22 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,405 Biotechnology companies, Camurus AB ranks better than 96.73% on this metric.

Camurus AB has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Camurus AB has Narrow Moat: Camurus AB has a solid position in the pharmaceutical industry with valuable patents and innovative R&D. It benefits from customer loyalty and some regulatory barriers, but faces strong competition limiting a wider moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Camurus AB might have Narrow Moat - Solid narrow moat.

Camurus AB  (OTCPK:CAMRF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Camurus AB Moat Score Related Terms

CAMRF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Camurus AB's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Camurus AB Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's Moat Score distribution charts can be found below:

* The bar in red indicates where Camurus AB's Moat Score falls into.


CAMRF
79GF Score
Camurus AB CAMRF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Camurus AB (CAMRF) has a Moat Score of 5 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Camurus AB ranks #46 out of 1405 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Camurus AB's Moat Score too high?
Camurus AB's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Camurus AB's value of 5 is 150% above this industry median. Based on the distribution chart, Camurus AB ranks #46 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #46 out of 1405 companies for Moat Score. This places Camurus AB in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Camurus AB's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.22, compared to a current price of $54.00 — trading 35.1% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Moat Score is 5 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $54.00 is trading 35.1% below its estimated GF Value™ of $83.22. GuruFocus considers Camurus AB to be Significantly Undervalued.

Key valuation signals for CAMRF:

  • Moat Score: 5
  • GF Value™: $83.22 vs. price of $54.00 (35.1% below fair value)
  • GF Score™: 79/100 with 1 warning sign
  • Industry Position: 150% above the Biotechnology median (#46 of 1405)

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score

Get the complete analysis for CAMRF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.00
Price
$83.22
GF Value